Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene Dose Response Study (JADE)
NCT00143273Phase 2Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Jun 2004
- Primary completion
- Mar 2006
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of lasofoxifene in osteoporosis (4 arms), sponsored by Ligand Pharmaceuticals. Primary endpoints: Bone Mineral Density changes at the spine at 12 months and Bone Mineral Density changes at the hip at 12 months. Started Jun 2004; status: completed.
02
Drugs
lasofoxifene
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00143273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143273.